Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation

P Strnad, M Siegel, Diana Toivola, K Choi, JC Kosek, C Khosla, MB Omary

Tutkimustuotos: LehtiartikkeliArtikkeliTieteellinenvertaisarvioitu

14 Sitaatiot (Scopus)

Abstrakti

Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting NIB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
AlkuperäiskieliEi tiedossa
Sivut2351–2357
Sivumäärä7
JulkaisuFEBS Letters
Vuosikerta580
Numero9
DOI - pysyväislinkit
TilaJulkaistu - 2006
OKM-julkaisutyyppiA1 Julkaistu artikkeli, soviteltu

Keywords

  • transglutaminase
  • Mallory body
  • keratin

Viittausmuodot